2018 International TTP Day participant fundraising directly impacts the Foundation's ability to provide ground breaking research funding.
The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.
The European Commission has granted marketing authorization for caplacizumab for the treatment of adults experiencing an episode of aTTP on August 31, 2018.